CHOLESTOSOME

Serial Number 88141747
606

Registration Progress

Application Filed
Oct 3, 2018
Under Examination
Nov 5, 2019
Approved for Publication
Sep 10, 2019
Published for Opposition
Sep 10, 2019
Registered

Trademark Image

CHOLESTOSOME

Basic Information

Serial Number
88141747
Filing Date
October 3, 2018
Published for Opposition
September 10, 2019
Abandonment Date
December 12, 2022
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Dec 12, 2022
Classes
005

Rights Holder

Therasyn Sensors, Inc.

03
Address
100 Crosby Blvd
Buffalo, NY 142263246

Ownership History

Therasyn Sensors, Inc.

Original Applicant
03
Buffalo, NY

Therasyn Sensors, Inc.

Owner at Publication
03
Buffalo, NY

Legal Representation

Attorney
R. Neil Sudol

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

40 events
Date Code Type Description Documents
Dec 12, 2022 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Dec 12, 2022 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Apr 26, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 25, 2022 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 25, 2022 EX5G S SOU EXTENSION 5 GRANTED Loading...
Apr 20, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 20, 2022 EXT5 S SOU EXTENSION 5 FILED Loading...
Jan 18, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 6, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 4, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 4, 2021 EXT4 S SOU EXTENSION 4 FILED Loading...
Nov 4, 2021 EX4G S SOU EXTENSION 4 GRANTED Loading...
Apr 28, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 26, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 26, 2021 EXT3 S SOU EXTENSION 3 FILED Loading...
Apr 26, 2021 EX3G S SOU EXTENSION 3 GRANTED Loading...
Oct 31, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 29, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 29, 2020 EXT2 S SOU EXTENSION 2 FILED Loading...
Oct 29, 2020 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 1, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 21, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 17, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 17, 2020 EXT1 S SOU EXTENSION 1 FILED Loading...
Apr 17, 2020 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 5, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 10, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 10, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 21, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 4, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 29, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 29, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 23, 2019 ALIE A ASSIGNED TO LIE Loading...
Jul 18, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 22, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jan 22, 2019 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jan 22, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 15, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 12, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 6, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005